IPCALAB

Ipca Laboratories Share Price

 

 

Invest in Ipca Laboratories with 3.27X leverage

Invest with MTF

Performance

  • Low
  • ₹1,490
  • High
  • ₹1,526
  • 52 Week Low
  • ₹1,168
  • 52 Week High
  • ₹1,635
  • Open Price₹1,500
  • Previous Close₹1,508
  • Volume299,342
  • 50 DMA₹1,429.91
  • 100 DMA₹1,408.46
  • 200 DMA₹1,401.91

Investment Returns

  • Over 1 Month + 3.49%
  • Over 3 Month + 14.62%
  • Over 6 Month + 4.65%
  • Over 1 Year -3.97%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.3
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 38,487
  • P/B Ratio
  • 5.2
  • Average True Range
  • 51.74
  • EPS
  • 39.02
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 17.83
  • RSI
  • 58.08
  • MFI
  • 65.83

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,517.00
+ 9.2 (0.61%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹1,466.75
  • 50 Day
  • ₹1,429.91
  • 100 Day
  • ₹1,408.46
  • 200 Day
  • ₹1,401.91

Resistance and Support

1524.6 Pivot Speed
  • R3 1,612.20
  • R2 1,588.60
  • R1 1,548.20
  • S1 1,484.20
  • S2 1,460.60
  • S3 1,420.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 9,357.41 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 13% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 9% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 58 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
2025-05-29 Audited Results & Final Dividend
2025-02-13 Quarterly Results
2024-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
30.04%
5.99%
10.42%
0%
6.55%
2.28%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director & CFO
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,517 As on 14 January, 2026 | 16:48

The Market Cap of Ipca Laboratories is ₹38486.9 Cr As on 14 January, 2026 | 16:48

The P/E ratio of Ipca Laboratories is 46.3 As on 14 January, 2026 | 16:48

The PB ratio of Ipca Laboratories is 5.2 As on 14 January, 2026 | 16:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23